Loading...
Product type and other environmental risk factors for inhibitor development in severe hemophilia A
ESSENTIALS: Treatment complications in hemophilia A: inhibitors development. Type of FVIII products: the latest updates on plasma‐derived or recombinant FVIII immunogenicity. SIPPET study, the first randomized study contrasting plasma‐derived FVIII and recombinant FVIII products. The impact of other...
Na minha lista:
| Udgivet i: | Res Pract Thromb Haemost |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055565/ https://ncbi.nlm.nih.gov/pubmed/30046724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12094 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|